Suraksha Diagnostic Ltd (NSE: SURAKSHA) Q1 2026 Earnings Call dated Aug. 11, 2025
Corporate Participants:
Unidentified Speaker
Somnath Chatterjee — Chairman and Joint Managing Director
Ritu Mittal — Joint Managing Director and Chief Executive Officer
Ravindra K S — Group Chief Financial Officer
Balgopal Jhunjhunwala — Regional Business Head
Analysts:
Unidentified Participant
Ashish Tendulkar — Analyst
Hitendra Pradhan — Analyst
Aditya Chheda — Analyst
Harsh Bhatia — Analyst
Siddhant Mayecha — Analyst
Anshul Agrawal — Analyst
Raman KV — Analyst
Presentation:
operator
Ladies and gentlemen, good day and welcome to the Suraksha Diagnostic Limited Conference call hosted by MUFG In Time India Private Limited. As a reminder, all participant lines will be in the listen only mode and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing STAR and then zero on your touchstone form. Please note that this conference is being recorded. I now hand the conference over to Mr. Ashish Tendulkar from MUSG. In time. Thank you. And over to you, Mr.
Tendulkar.
Ashish Tendulkar — Analyst
Good morning, ladies and gentlemen. From the management team we have Dr. Somnath Chatterjee, Chairman and Joint Managing Director, Ms. Ritu Mittal, Joint MD and CEO, Mr. Ravindra KS Group CFO and Mr. Balgopal Junjanwala, Regional Business Head. Before we proceed with this call, I would like to mention that some of the statements made in today’s call may be forward looking in nature and may involve risk and uncertainty. For more details, kindly refer to the investor presentation and other filings that can be found on the company’s website and stock exchanges. Now with that, I would like to invite Dr.
Somnath Chatterjee for his opening remarks. Thank you. And over to you, sir.
Somnath Chatterjee — Chairman and Joint Managing Director
Good morning everyone. I’m pleased to welcome you to the quarter one FY26 earnings conference call at Shuruksha Diagnostics. Let me start by talking about a major milestone that marks a transformative step in our journey. In March 2025, our board approved an investment in Fitomat Wellness Private Limited resulting in the acquisition of a 63% stake on April 9th. This acquisition marks our formal entry into the field of genomic medicine. A space we believe which holds immense potential for innovation and impact. Fitomat operates in the healthcare segment with a strong focus on pregnancy care, women’s ultrasound scanning, prenatal diagnostics, genetic counseling and medical training for doctors.
We see significant synergies with our existing operations and believe this move opens new avenues for long and sustainable growth. On the operational front, we have continued to quickly expand our footprint. During this quarter, we have successfully added 8 new centers. With these additions, our network grew to 58 centers at the end of June 2025. Subsequently, to the end of the quarter, we share another very important news with all our stakeholders. We are excited about the launch of Suraksha Genomics, a dedicated vertical offering advanced genetic and molecular testing services. You would be kind enough to note that this is the first complete genomic laboratory facility which is available in the whole of Eastern India.
It involves the whole of Cytogenetics, the whole of next generation sequencing in multiple platforms. We believe this launch ties nicely with our fetal medicine deal, the Phetomat deal, as we can leverage advanced genomic testing for our prenatal care with these bridges. I will now invite our CEO, Mrs. Mittal to elaborate on the operational performances and updates during the quarter and Beyond.
Ritu Mittal — Joint Managing Director and Chief Executive Officer
Thank you, Dr. Chatterjee. Good morning everyone. I’m very pleased to provide all the relevant operational updates. We have opened eight new centers in the first quarter. One out of this one large center, one medium center, four small centers and two PPP centers. We have closed two HLMs, one because the term expired and the other because we’ve opened a new center close by. We are also closing the Shillong PPP as the government is planning a medical college in that location. The government is however, compensating us for all the expenses incurred by us and we plan to open a big center in Shillong which will be completely owned by Suraksha Diagnostics.
So when you look at the figure, it will look like we have just added three centers. This is because we have closed three centers and we have taken all the PPP centers that we have opened under our subsidiary SRPL. We are very confident of delivering 15 to 18 centers in this current year. Our forward looking strategy is ambitious and positions us on a path to propel our growth trajectory even further. We are expanding into whole genome and metagenomic testing, integrating AI assisted variant interpretation to enhance accuracy and developing population scale genomic screening programs. We are also making significant strides in fetal medicine starting with our four flagship locations.
We aim to scale these capabilities across 15 to 18 centers in FY26 and eventually extend these services to even the remotest corners over the next two to three years. In Eastern India, where we already enjoy a robust presence, remains under penetrated, offering opportunities to deepen our footprint and catalyze the next phase of growth. As Dr. Chatterjee already mentioned, we are the only genomic testing lab in the whole of Eastern India and Suraksha has made an investment of around 22 crores to establish the state of the art genomics lab. Finally, I want to take a moment to express our heartfelt appreciation to all our stakeholders for your continuous trust and support which inspires us to reach new heights and deliver the best possible care.
With that, I would like to hand over the call to Mr. Ravindra for the brief commentary on the company’s financial performance during quarter one.
Ravindra K S — Group Chief Financial Officer
Thank you Vishuma. Good morning. Everyone, let me now walk you through a brief overview of our financial performance for the quarter ended 30 June 2025. For Q1 FY26, the total income stood at.
operator
So sorry to interrupt, but your voice seems to be distant. Can you come closer to the device and speak?
Ravindra K S — Group Chief Financial Officer
Yeah. For Q1, let me repeat. For Q1 FY26, the total income stood at 734.92 million, reflecting an 18.83 year on year increase over the same period. In the previous year, EBITDA grew by 13.51% to 246.56 million. With EBITDA margin at 33.97% PAT for the quarter rose by 19.67% year on year to 91.75 million. Consequently, our PAT margin of 12.64% remained largely stable for the quarter. Looking ahead, we expect our EBITDA and margin to improve as our centers scale and mature. With higher throughput, improved operating leverage and tighter cost control, we anticipate meaningful margin expansion, especially in our mature centers.
As the newer centers stabilize and begin contributing significantly, we foresee a stronger and more profitable financial profile across the network. The consistent growth across revenue EBITDA coupled with healthy margins and strong operating metrics underscores our ability to execute effectively and drive sustainable, profitable growth. That concludes my remarks and I would now request the moderator to open the floor.
Questions and Answers:
operator
Thank you very much. We’ll now begin the question and answer session. Anyone who wishes to ask a question may press STAR and one on their touchstone telephone. If you wish to remove yourself from the question queue, you may press STAR and two participants are requested to use hand zips while asking a question. Ladies and gentlemen will wait for a moment while the question queue assembles. The first question is from the line of Hitendra Pradhan from Maximal Capital. Please go ahead.
Hitendra Pradhan
Hello. I hope I’m audible. Thanks for the opportunity. I wanted to ask a bit about the competitive landscape in the regions that you’re currently operating. So, you know, like, what is the common preference among the patients in terms of, you know, going to the diagnostic center versus hospitals? So how do you think that, you know, the hospitals are serving the needs when it comes to diagnostics and all these things?
Somnath Chatterjee
It’s a, it’s a. It’s a very interesting question. Because of late we see hospitals getting into diagnostics in a more reformed way. But ultimately, if you look at the whole scenario that what percentage of patients actually end up in hospitals? So the majority of the patients today will consult In India where diagnostics is mainly reactive, the patients will go and consult a doctor who will give them some diagnostic tests to be performed. And these are done basically at local accredited diagnostic centers. There are two reasons behind this. One is accessibility is much easier to these diagnostic centers across the Indian geography.
The second is the known diagnostic center happens to be at least 30 to 40% cheaper than the hospital diagnostics. So these are the two main reasons that today the majority of the patients will always approach an independent diagnostic center rather than a hospital.
Hitendra Pradhan
Thank you, sir. So, so you, you meant to say that the diagnosis centers are currently cheaper than the hospitals. Like 30 to 40%. Like this is across the different services. Like, like you know, the advanced as well as the usual.
Somnath Chatterjee
You see for the, for the advanced test the hospitals will not even have the setup. Today if you look at high end tests like genomics or like city medicine tests like amniocentesis or Corian bilus sampling followed by a series of genomic tests like NIPT or microadic, most of the hospitals will lack both the infra and the personal necessity to do this. So the high end tests are almost completely confined to the larger diagnostic centers in India. And also there are specialized genomic labs which only specializes in genomic tests. Similarly, high end ultrasounds or high end Mr.
Protocols are also. Because in a hospital you are limited by the resources that you have. Whereas in a diagnostic center your reach to the radiologist or the pathologist is much larger. So this facilitates the independent diagnostic centers a lot more than hospitals. Hospitals would do much more routines and that too mainly for their IPD patients.
Hitendra Pradhan
Okay sir, understood. So my second question is for the. Cfo, sir, like what is the. Like the rental of the lease payment for the quarter.
Ravindra K S
Can you please repeat the question?
Hitendra Pradhan
Yeah. What is the rental payment for the quarter?
Ravindra K S
Total payment? Rental. It varies from total other expenses. When you see on my financial. Which is 17% of my total revenue which includes around 8 to 9% which is pertinent to rent.
Hitendra Pradhan
Okay, thank you.
operator
Thank you. The next question is from the line of Aditya Cheddar from Ingrid Asset Management. Please go ahead.
Aditya Chheda
Morning Dr. Chatterjee. My question is if you can outline the key drivers of the volume growth that we’ve had of almost 26%. And since the revenue growth is at around 19% the revenue per test has slightly declined. If you can outline the key drivers of the same. That’s my first question.
Ritu Mittal
So the revenue per patient has declined a little because the B2B and the B2C mix is changing since We’ve set up a genetic lab. We are also trying to do a lot more of B2B die ups. Historically we used to have 94%, 96% as B2C customer and 4% was B2B. Now we are trying to increase our B2B reach and therefore the revenue per patient is a little lower than last quarter.
Aditya Chheda
And the same reason should be attributed to higher volume growth. Right? Yes, got it. My next question is on the investment in genomics. We’ve highlighted that we will invest another 45 odd crores. If you can outline your view and directionally, you know, talk more about what kind of revenue targets or you know, the addressable market etc you envision and how different it will be from setting up just pathology lab, etc. Some details around that. Thank you.
Somnath Chatterjee
The question is like opening up a Pandora’s box. So whatever development you will see in medicine happening over the next decade will mainly come from the field of molecular biology. And this is not only confined to diagnostics, this will spread across. Genomic study will also engulf treatment. Today. When we do, when we are covering an oncology patient, suppose I’ve got a colon cancer, so there are four, five drugs for that colon cancer.
Now it is only the genomic study, the next generation sequencing panel that will determine which drug will be most effective for this patient. So you see, today it is. Today we are using this technology only for oncology patients and also hematological oncology patients, liquid cancers like leukemia. But tomorrow this will go and engulf almost all diseases. Because as a human being, phenotypically we. Are all different and the same medicine. May not work the same way in two patients. So as medicine progresses and becomes more and more personalized, you will be using genomics more and more. And today what we define as high. End, in the next five, six years.
This will turn out to be routine. The biggest challenge in this is the manpower. Technically relevant, qualified people are very limited in this study. As a matter of fact, in Shuruka. We have taken about 18 to 19. Months to build this team. You know, you not only need PhD. Scholars who will run these tests, you need a bunch of bioinformatic engineers sitting at the back to study your next gen sequencing reports. So we believe that this will be one of the main drivers of growth in coming years.
And Shurukkhar being the leading diagnostic chain in the east and northeast, if it can deliver the right results with the right kind of turnaround time, there is no doubt in our mind that we will establish ourselves as the Principal leaders of genomics in east and Northeast. Because as we have repeatedly said, and you know this, that diagnostics at the end of the day remains a regional play.
So there will be genomic labs which will also be regional and will control that territory. They will be the first pathfinders in this and Shuruka plans to be there. We have already launched the entire panel of. We have two multiple platforms to do next generation sequencing. We have the biggest cytogenetic labs, we have a microarray, we have a sender, we have all the equipments necessary to deliver and we have already started delivering on those lines.
Ritu Mittal
So it’s really good to look at the financial part of it because these are high end, esoteric tests. The uptake will definitely be slow. But this is more like investing in the future. And Suramsha being the leading player in east, we definitely also plan to keep adding newer tests to serve our finders.
Aditya Chheda
I understood that was very helpful. I wish you all the best. Thank you.
operator
Thank you. The next question is on the line of Harsh Bhatia from Bandhan Mutual Fund. Please go ahead.
Harsh Bhatia
Yeah, hi, good morning. Am I audible?
operator
Yes, you are.
Harsh Bhatia
Yeah. Thank you. Just two quick clarifications. One is ma’, am, I think so you are halfway through the commentary, but I joined a bit late in terms of the center edition part. Just you could help us bridge the gap. I think you already made a few comments, but if you could, again, sort of, it will be a little bit more helpful.
Ritu Mittal
Okay. So last year, if you will recall, we ended with a count of 55 centers. Okay. And so we closed down three centers. Out of these, two were HLMs. So one we came to the end of the term and the second one we have closed down because it only had a city scan the hospital premises. And now we have opened our own center close by. Third is the PPP that we had with the Shillong government. Now the government wants to set up a medical college in the same premises. So therefore, obviously we are forced to vacate that area and they will compensate us for all the financial losses that we’ve incurred over the years.
So now that brings the count to 52. And if you see we’ve closed at a count of 58. So therefore we’ve added six centers here and we’ve added two PPP centers under the name of SRPL, which is a subsidiary company.
Harsh Bhatia
Okay. And from the Shillong perspective, would you be able to highlight what is the broader level of. Broader nature of losses that we have incurred over the past Few years. And how would we account for it? Once it is reimbursed by the government.
Ritu Mittal
It is around 4 crores. So this was the cost that we’ve incurred over the years and the government will compensate us for this. And this will again be used like capex for us in the next ongoing projects.
Harsh Bhatia
Cumulative.
Ritu Mittal
Yes.
Harsh Bhatia
Okay. And from an EBITDA perspective in the. Fourth quarter we had highlighted that there. Were some one off losses in terms of credit provisioning, GST payments and some genomic lab one offs. Is there anything in particular we should keep in mind for the first quarter from the EBITDA perspective?
Ritu Mittal
The only thing I would like to highlight here is that if I look at all the centers that have been operational for more than two years now, their EBITDA margin comes to around 37% for us. And we have added around 12 to 13 centers which are, you know, like eight centers are not even four months old. And the balance 12 centers are also, you know, around 15 months, 16 months. So where we look at centers that are above one year old, the EBITDA margin is around 17%. And obviously these less than four months old are loss making.
Therefore our IP EBITDA comes to 34. But if I were to look at two years mature centers, our EBITDA margins are 37%. So slowly, you know, as we keep scaling up the new centers, their EBITDA will get added. But when we are going on opening new centers again, that takes a little bit of a beating. But in the long run it will pay off. So it’s like, you know, you want healthy margins with a robust growth that is not happening. We are planning on adding and achieving a number of hundred in the next two to three years and then maybe stabilize the margins.
Harsh Bhatia
And just one last clarification. We are saying that we will add 15 to 18 centers for the entire year. That is on a gross level basis, not at a net addition number because there might be a few more center closures that is possible. So this 15 to 18.
Ritu Mittal
So there might be two collection points that we might shut down because these collection points center where we just draw blood. So when we see that the collection center is performing very well, we bring up a small center close to it and then this collection center does not make sense, so we shut it down. So there might be one or two cocos that we will close, but that’s about it.
Harsh Bhatia
Thank you.
operator
Thank you. Before we take the next question, a reminder to the participants. Anyone who wishes to ask a question may press star and one on their touchstone Telephone. The next question is from the line of Siddhan from Tusk Investment. Please go ahead.
Siddhant Mayecha
Yeah, good morning everyone. Like you highlighted that. Hello. Am I audible? Yeah, ma’, am, like you highlighted, we have opened eight centers this quarter. So these centers include the federal acquisition also.
Ritu Mittal
No, that will come in the next quarter.
Siddhant Mayecha
Okay, so that is, I guess federal man has two centers. So that is not included in this, right?
Ritu Mittal
No, it is not.
Siddhant Mayecha
Okay. And ma’, am, our revenue has grown close to 19%. But our EBITDA is like around 14, 15%. So the new centers has contributed any losses?
Ritu Mittal
Yes, the centers that have, you know, so the pre operating expenses are also written down. I mean the goes away for that also. And as the center opens it takes time to pick up and therefore the first few months definitely it incurs a hit on the ebitda.
Siddhant Mayecha
How much was that amount for this quarter? Like the new center losses?
Ritu Mittal
I think around 3 to 4 crores.
Siddhant Mayecha
3 to 4 crores. So we are expecting this like from the next quarter it will be break even. So.
Ritu Mittal
Yes, so next quarter definitely anyways is a better quarter for diagnostics. So we definitely think margins will be better for the next quarter. But overall one has to be very mindful of the fact that as we are adding so many new centers. So. Obviously you cannot expect, like I mentioned, all the centers that are more than two years old together have an EBITDA of 37%.
Siddhant Mayecha
Right now.
Ritu Mittal
But the centers which are relatively new and that too as I say again, 12 to 15 months old have a margin of around 17 to 18. No, 21%.
Siddhant Mayecha
Okay, okay. So this quarter it was three to four. Yes, three to four. Okay. And on the centers like we have closed three centers. So what was the revenue contribution and EBITDA contribution from those centers?
Ritu Mittal
Very miniscule. I will show the three centers.
Siddhant Mayecha
Yeah.
Ritu Mittal
You have to give me some time to give you this figure. So it was 15, 20 lakhs of monthly revenue from these three centers combined. And the EBITDA was negative. They have not contributed to lower margins. The new centers have made the margin. This has in fact bettered our margin because these were loss making centers.
Siddhant Mayecha
So ma’, am, if I just remove the new center losses, that means this quarter the EBITDA figure was close to 26, 27th year.
Ravindra K S
19S. Currently we are at 25.
Ritu Mittal
Yeah. So if we add back, if we add back the losses, so it will be around 27, 20.
Siddhant Mayecha
Okay, thank you ma’. Am. I’ll get back in the queue for further questions.
Ritu Mittal
Okay, sure.
operator
Thank you. The Next question is from the line of Anshul Agarwal from MK Global. Please go ahead.
Anshul Agrawal
Hi. Thank you for the opportunity. Hope I’m audible.
Ritu Mittal
Yes, you are great.
Anshul Agrawal
Ma’, am, if you could just help us understand what has caused the 25, 26% volume growth. I understand that, you know B2B is a contributor to that, but if you could just bifurcate this growth between B2C and B2B.
Ritu Mittal
For that I’ll have to get back to you. But the overall volume growth is because of the number of centers that we’ve added and the ecoteric test that we’ve started.
Somnath Chatterjee
It is mainly because of the strategic location of the new centers that has opened. This has genuinely helped the volume growth. If you look that Shuruksha’s overall strategy of growing concentrically has proved to be a hit here. So the newer centers, which are a little distance away from our previous centers have started contributing positively not only to their own self but to the previous centers as well. So the fudge is there in the market.
Ritu Mittal
Because like we mentioned, we’ve added B2B business which are mainly package oriented and therefore the number of tests go up. That is one factor that’s contributing. And of course the newer centers that we’ve added, that is also adding to the test.
Anshul Agrawal
Got it. Just some more clarity on this. So I think if you’re doing more B2B businesses, would that be more bundled testing? Because our test per patient is already at 5.5, 5.6. Would this go up further in your opinion going forward? If we Keep adding more B2B volumes.
Ritu Mittal
It might. When we add corporate business, which is again B2B where you know, the health checkups for the employees happen. So all those are bundled tests. But when we talk about PSUs like CGHS and also there the bundling of test does not happen. So overall it will go up, but not to a noticeable extent.
Anshul Agrawal
And ma’, am, what would be the margin profile differential between B2B and B2C testing? Would this sort of weigh in on margins? Because generally from what we have seen in the industry, B2B comes at a slightly lesser margins than B2B than B2C in the industry.
Ritu Mittal
When we look at B2B, a lot of it is collection center business where people are giving crazy prices to pick up samples from the districts. But when we at Suraksha, when we talk about B2B, this is basically corporate sales where the discovery account margins are not so big and we talk about esoteric sales, that means the genetic Lab tests, which again are very high end and therefore you don’t need to give heavy discounts. We are not talking about the collection center business where the discounting is to the tune of 70 to 80%. We are not talking about that kind of B2B here.
Anshul Agrawal
Got it. So in your opinion, again, margin differential would not be meaningful for the B2B and the B2C business for Suraksha. Would that understanding make fair?
Ritu Mittal
Absolutely.
Anshul Agrawal
Got it. And if you just help me understand who would be these end customers for these esoteric tests in the B2B profile? Would it be pharma companies? Would it be any research divisions?
Ritu Mittal
So this will actually entail everything. It will also be from hospitals where new babies are being born, also from consultants who are practicing independently and there can definitely be pharma diagnostics also. So therefore the lab has been set up with all these inflows in mind.
Anshul Agrawal
Got it. One more question on Fetomat, what would be the revenue contribution in the current year from Fatomat? What could that be? The contribution to Suraksha for the current year.
Ritu Mittal
So for Fetomat it will be around in this year, first quarter. It is.3cr, 1.4cr, 1.4cr.
Anshul Agrawal
And would this sort of accelerate now that it has come under our umbrella or what are our plans for fetomat, ma’?
Ritu Mittal
Am? Yes, definitely it will accelerate and therefore the acquisition has been done. Like Dr. Chatterjee mentioned, we also plan to give these fetal services to begin with in four of our flagship centers and then we want to keep expanding the reach of Fitig medicine throughout our network.
Anshul Agrawal
Got it. Just one last question. If I can squeeze in, I think a couple of quarters back, we mentioned that we’re despite the center additions, we are planning to grow our EBITDA margin profile by around 250 to 300 basis points every year. But as per commentary that you stated, probably FY26 and 27 may not see that kind of jump in margins.
Ritu Mittal
Yes, it may not because we are planning to add 18 centers this year.
Anshul Agrawal
Okay. And that run rate should continue in 27.
Ritu Mittal
Like I mentioned, we want to touch your number of hundred and then work on the margins. But I am again I would like to mention the fact that the margins will not take a big beating because the most, I mean the biggest expense for us is the HO expense which is ultimately going to get divided. Because. Of economies of scale. So therefore I don’t see much of a change in the margin pattern in spite of addition. But you know, to talk about increase every Quarter becomes a little challenging when you’re adding so many centers.
Anshul Agrawal
Noted. All the very best, ma’. Am. That’s it for my end. Thank you.
Ritu Mittal
Thank you.
operator
Thank you. The next question is from the line of Varun Mishra from MNS Associates. Please go ahead.
Unidentified Participant
Hi ma’. Am. Thank you for the opportunity and congratulations on a good set of numbers. I had a couple of questions from my end. So like, like what has been the level of capex in terms of in the year FY26? Like are we planning to do any capex on the geonomics vertical in FY26 or 27 and do we take to plan, like plan to take some debt on board as well? Thank you.
Ritu Mittal
So we like we have mentioned earlier also we plan to incur a capex of around 70 crores and we don’t really need any debt for this. We have internal accruals and if required we might take some equipment financing.
Unidentified Participant
Ma’, am, currently are we looking for any inorganic growth opportunities? Elaborate on specific areas of interest like if we might get into an acquisition.
Ritu Mittal
We are all, all the time exploring organic inorganic opportunities and we are focused in East India so we are looking at nearby states and also in West Bengal if we find something good at the. At a good price.
Unidentified Participant
All right. You had previously highlighted the strategic focus on the B2B partnerships. So could you provide us the update on the partnerships which has been evolving around for us. Are we seeing any meaningful traction on board like in terms of corporate clients?
Somnath Chatterjee
No, you see with the addition of genomics, what is happening is almost all hospitals, the larger hospitals in east and northeast will become our B2B partners. A large number of medical colleges also which does a lot of academic work will also be our B2B partners. So that is, that was one of the principal intent of our working with genomics. We have already signed two MOUs. One with IIT Kharagpur for research on microfluidics and the other which is in the process of Indian Institute of Chemical Biology for work on genomics. So these kind of collaborations also leverage our position to a huge extent.
Unidentified Participant
All right, and like a last question from mine, like as we have seen the margins have been good in terms of comparison for year on year as well as how much of this could we see sustaining in the further quarters? Could you look like, just tell me. About that.
Ritu Mittal
In the further quarters like in quarter two we definitely expect an improvement because it’s a better quarter for the industry. And overall we would definitely like to always try to maintain a margin of around 35%.
Unidentified Participant
This is on the annual basis, right? 35 percentage.
Ritu Mittal
Yes. Yes.
Unidentified Participant
All right. That’s awesome. Thank you. All the best.
Ritu Mittal
Thank you.
operator
Thank you. The next question is from the line of Raman KV from Sequent Investments. Please go ahead.
Raman KV
Hello, ma’. Am. Thank you for allowing me to answer the question. I just want to understand what are, what is the revenue growth guidance for the current year?
Ritu Mittal
So the revenue growth guidance that for the current year is 15%.
Raman KV
Okay.
Ritu Mittal
And the guidance is around 34 to 35%
Raman KV
epidural margin. So 15% revenue growth with 30 to 34 to 35% EBITDA margin. Am I right?
Ritu Mittal
Yes.
Raman KV
And ma’, am, with respect to volume, can you give any figures on volume growth?
Ritu Mittal
You know, volume growth is a big gray area because some people are talking about one package test. To have 20 tests, one CBC can be treated as 17 parameters. So it becomes. It’s a very. So we really don’t know how to calculate this volume growth that we talk about.
Raman KV
Okay.
Ritu Mittal
Parameter, you know, people are doing whatever suiting them.
Raman KV
Okay. And mama, my second question is with respect to the. The recent foray into general. Mix or. Genetic testing and advanced molecular testing. I’m used in the pivot highlighted. 22 crores investment has been made and you expect to expect an incremental revenue of around 40, 45 crores over by next two years. So this is, is this like cumulative 40, 45 crores revenue over the period of two years or by the end of the second year you are expecting 40 crores of revenue.
Ritu Mittal
We are talking about cumulative.
Raman KV
Okay. Thank you.
operator
Thank you. The next question is from the line of Ranbir Singh from Yashashree Securities. Please go ahead.
Unidentified Participant
Hi ma’. Am. Hi, sir. Hi ma’. Am. My question was around the competitive intensity in the industry. Like a few of the competitors used to take a name. Vidya Diagnostics inaugurated to open the center in Kasbah. And now they are planning an additional three hubs in FY26. So how do you see the competitive intensity in the industry right now?
Ritu Mittal
Competition has always been there. And you know, it is like we always emphasize the fact that this is a regional business. And therefore for a new entrant to come in and take some space is a matter of a lot. I mean matter of time. So it’s going to take a long time just opening centers. Like even if we were to go to Hyderabad and try to open centers and it’s going to take a long time for us to succeed because it’s a trust based industry and Trust builds over time, you know, so first the patients have to trust you, then the doctors have to trust you.
And to be able to deliver the same quality of reports and services, it is a little bit of a. I mean, it’s not so easy. Setting up is easy, but you know, getting the market share is a time taking affair. So, you know, like we’ve always had Dr. Lal, we’ve had Metropolis, we’ve had SRL. So all of them have been in the eastern region for decades now. But that doesn’t really slow down our growth because anyway, these businesses face more of B2B business. And we are a B2C facing business. So the customer comes to us because they trust the brand.
And of course there is also a lot of local competition. And it has always been there. It’s not a new thing. So I think it just makes you strive to be better.
Unidentified Participant
Okay, ma’, am, all the best. Congratulations on a good set of numbers.
Ritu Mittal
Thank you.
operator
Thank you. The next question is from the line of Siddhan from Tusk Investments. Please go ahead.
Siddhant Mayecha
Ma’, am, just a follow up question. Like in the presentation it’s written that we have 18 large centers and in the previous quarter it was 14. So have we added four large centers?
Ritu Mittal
No, in the presentation must be 15.
Siddhant Mayecha
It’s written 18.
Ritu Mittal
18. Just a minute.
Siddhant Mayecha
18 hub centers.
Ritu Mittal
But we currently have 16. Actually one has opened in this quarter and we had 15 till the last quarter.
Siddhant Mayecha
So ma’, am, can you just give us the breakup of the 60. Like 15 is large and the rest 45 is medium to small.
Ritu Mittal
Yes. Yes.
Siddhant Mayecha
Okay. So it’s a printing error, right?
Ritu Mittal
Yes.
Siddhant Mayecha
Okay. Okay. Hello.
Ritu Mittal
Yes, go ahead.
Siddhant Mayecha
Yeah. No. Okay, that will be it. Thank you.
Ritu Mittal
Thank you.
operator
Thank you. As there are no further questions, I would now like to hand the conference over to the management for closing comments.
Somnath Chatterjee
Thank you very much. We will strive harder and hopefully the results will keep on improving in the coming months. And we plan to meet you guys again at the end of this current quarter with better results and better performance. Thank you once again for being with us.
operator
Thank you very much on behalf of Suraksha Diagnostic limited. That concludes this conference. Thank you for joining us. And you may now disconnect your.